FDA to Miss Savara’s User Fee Date as BLA Review Continues
FDA will not meet its 11/22 user fee action date for Savara’s BLA seeking approval of molgramostim inhalation solution for treating autoimmune pulmonary alveolar proteinosis (aPAP), according to the company.
The agency’s review is continuing, and no revised action date has been provided.
Molgramostim is an investigational recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) designed to be administered using the investigational eFlow Nebulizer System.
Autoimmune PAP is a rare lung disease characterized by the abnormal accumulation of surfactant in the alveoli, impairing gas exchange.
In healthy lungs, immune cells called alveolar macrophages clear excess surfactant, a process that depends on GM-CSF signaling. In patients with autoimmune PAP, autoantibodies neutralize GM-CSF, preventing macrophages from adequately clearing surfactant.
The resulting accumulation of surfactant impairs gas exchange and can cause shortness of breath, coughing and fatigue, according to Savara.